Diabetes e Insuficiencia Cardíaca
Author:
Open Access
- 30 March 2020
- journal article
- review article
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 1 (1) , 6-14
Abstract
Diabetes Mellitus (DM) is a chronic non-communicable cardio-metabolic disease that causes macro-vascular complications such as atherosclerosis, coronary disease and heart failure (HF). There is a bidi- rectional relationship between HF and DM, HF being the second most frequent initial cardiovascular event in patients with diabetes. It may even be the first cardiovascular complication, before acute my- ocardial infarction.DM can lead to HF through mechanisms mediated by atherosclerosis and non mediated by it. In the first case, cholesterol is deposited in coronary arteries, favored by the presence of other risk factors. In the second case, the myocardium is directly affected leading to structural and functional changes through non-atherogenic mechanisms (called Diabetic Cardiomyopathy).The treatment of HF with reduced ejection fraction in the diabetic patient does not differ from that of the non-diabetic population, the triple neurohumoral block must be achieved. In the case of patients with HF with ejection fraction preserved to date, we do not have specific therapy to reduce cardiovas- cular morbidity and mortality. In the diabetes treatment of the patient with HF, sodium-glucose type 2 cotransporter inhibitors (SGLT2i) clearly stand out. In addition to their glucosuric and natriuretic effect, they have pleiotropic effects that produce metabolic, hemodynamic and cellular viability effects preventing apoptosis and cell death. Finally, the clinical benefits of SGLT2 inhibitors in HF go beyond glycemic control, as demon- strated by the DAPA-HF study; initiating a new era in the treatment of patients with HF with reduced ejection fraction.Keywords
This publication has 31 references indexed in Scilit:
- Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypesEuropean Heart Journal, 2015
- Diabetic CardiomyopathyCirculation, 2015
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million peopleThe Lancet Diabetes & Endocrinology, 2015
- Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetesCardiovascular Diabetology, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Eplerenone and New-Onset Diabetes in Patients with Mild Heart Failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)European Journal of Heart Failure, 2012
- Diabetes increases apoptosis and necrosis in both ischemic and nonischemic human myocardium: Role of caspases and poly–adenosine diphosphate–ribose polymeraseThe Journal of Thoracic and Cardiovascular Surgery, 2007
- Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic DysfunctionCirculation, 2004
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Glycemic Control and Heart Failure Among Adult Patients With DiabetesCirculation, 2001